Matrix Service Company
NASDAQ:MTRXEngineering & Construction
+$0.38 today
- Market cap
- $240.86M
- Beta
- 0.99
- P/E (TTM)
- -26.3
- EPS (TTM)
- -$0.53
Volume 0.58M
Average 0.28M
MTRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Matrix Service CompanyNASDAQ: MTRX
Research & Development · Q3 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-30 | 0 | — |
Research & Development vs competitors
How MTRX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for MTRX, versus a peer median of 0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.01B USD | +136110.5% | +24.4% | 18184.8% | |
| LTM Mar 2026 | $117.38M USD | -11.1% | -0.8% | 26.3% | |
| LTM Mar 2026 | £106.28M GBP | — | +13.6% | — | |
| LTM Mar 2026 | $17.01M USD | +0.7% | +0.4% | 9.3% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $4.18M USD | +25.8% | -18.0% | 1.6% |
| LTM Mar 2026 | $1.95M USD | -61.5% | -17.1% | 0.3% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MTRX) | — | +0.7% | -0.2% | 0.3% | |
Competitors are the stored peer set for MTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 673.4M | 707.78M | 795.02M | 728.21M | 769.29M |
| Cost of Revenue | 640.63M | 708.99M | 764.2M | 687.74M | 729.61M |
| Gross Profit | 32.77M | (1.21M) | 30.82M | 40.47M | 39.68M |
| Gross Margin | 4.9% | -0.2% | 3.9% | 5.6% | 5.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 69.76M | 67.69M | 68.25M | 70.09M | 71.17M |
| Operating Expenses | 76.51M | 86.65M | 83.71M | 70.59M | 74.75M |
| Depreciation & Amortization | 17.86M | 15.25M | 13.69M | 11.02M | 10.01M |
| EBITDA | (23.85M) | (40.08M) | (37.04M) | (12.86M) | (18.47M) |
| EBITDA Margin | -3.5% | -5.7% | -4.7% | -1.8% | -2.4% |
| Operating Income | (43.75M) | (87.85M) | (52.89M) | (30.11M) | (35.07M) |
| Operating Margin | -6.5% | -12.4% | -6.7% | -4.1% | -4.6% |
| Interest Income | 126K | 90K | 290K | 1.34M | 6.65M |
| Interest Expense | 1.56M | 2.95M | 2.02M | 1.13M | 518K |
| Other Income / Expenses | 484K | 29.57M | 126K | 5.1M | 6.07M |
| Income Before Tax | (43.26M) | (58.28M) | (52.76M) | (25.01M) | (29M) |
| Pre-Tax Margin | -6.4% | -8.2% | -6.6% | -3.4% | -3.8% |
| Income Tax Expense | (12.04M) | 5.62M | (400K) | (36K) | 464K |
| Net Income | (31.22M) | (63.9M) | (52.36M) | (24.98M) | (29.46M) |
| Net Margin | -4.6% | -9.0% | -6.6% | -3.4% | -3.8% |
| EPS (Basic) | (1.18) | (2.39) | (1.94) | (0.91) | (1.06) |
| EPS (Diluted) | (1.18) | (2.39) | (1.94) | (0.91) | (1.06) |
| Weighted Avg Shares | 26.45M | 26.73M | 26.99M | 27.38M | 27.77M |
| Weighted Avg Shares (Diluted) | 26.45M | 26.73M | 26.99M | 27.38M | 27.77M |
Matrix Service Company
NASDAQ:MTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.